Triple threat: new combo tackles Hard-to-Treat melanoma
NCT ID NCT02910700
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This phase II trial tests two different three-drug combinations in people with advanced BRAF-mutated melanoma that has spread or can't be removed surgically. One group gets nivolumab (immunotherapy) plus trametinib and dabrafenib (targeted drugs); the other gets nivolumab plus encorafenib and binimetinib. The goal is to see how well these combos shrink tumors and what side effects occur. About 52 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE BRAIN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab, trametinib, dabrafenib, encorafenib, binimetinib
What this could lead to
If successful, this could offer a more effective treatment option for people with advanced BRAF-mutated melanoma that has stopped responding to standard immunotherapy.
What could go wrong
This is a small, early-phase trial (52 participants) and results may not apply to everyone. Combining multiple drugs can increase side effects, and the approach may not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.